Indefinite-Lived Intangible Assets
Pfizer Indefinite-Lived Intangible Assets decreased by 2.6% to $21.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.8%, from $19.35B to $21.64B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Intangible Assets shows an upward trend with a 37.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful brand acquisitions or strengthening of brand equity, while a decrease may indicate impairment charges or divestitures.
Detailed definition
These are non-physical assets, such as iconic brand names or trademarks, that are expected to generate cash flows for an...
Peer comparison
High for consumer staples companies with strong global brand portfolios like PepsiCo or Nestlé.
indefinite_lived_intangible_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.54B | $4.50B | $4.43B | $9.92B | $9.83B | $9.63B | $13.16B | $0.00 | $0.00 | $0.00 | $24.78B | $22.93B | $22.65B | $22.65B | $19.56B | $19.35B | $18.67B | $17.81B | $22.22B | $21.64B |
| QoQ Change | — | -0.8% | -1.5% | +123.9% | -0.9% | -2.0% | +36.6% | -100.0% | — | — | — | -7.5% | -1.2% | +0.0% | -13.6% | -1.1% | -3.5% | -4.6% | +24.8% | -2.6% |
| YoY Change | — | — | — | — | +116.7% | +114.0% | +196.8% | -100.0% | -100.0% | -100.0% | +88.4% | — | — | — | -21.1% | -15.6% | -17.5% | -21.4% | +13.6% | +11.8% |
Indefinite-Lived Intangible Assets at Other Companies
Frequently Asked Questions
- What is Pfizer's indefinite-lived intangible assets?
- Pfizer (PFE) reported indefinite-lived intangible assets of $21.64B in Q1 2026.
- How has Pfizer's indefinite-lived intangible assets changed year-over-year?
- Pfizer's indefinite-lived intangible assets increased by 11.8% year-over-year, from $19.35B to $21.64B.
- What is the long-term trend for Pfizer's indefinite-lived intangible assets?
- Over 5 years (2020 to 2025), Pfizer's indefinite-lived intangible assets has grown at a 37.2% compound annual growth rate (CAGR), from $4.58B to $22.22B.
- What does indefinite-lived intangible assets mean?
- The value of brand names and trademarks that do not expire and are not subject to periodic amortization.